Crinetics Pharmaceuticals, Inc. 6Z4.F Stock
Crinetics Pharmaceuticals, Inc. Price Chart
Crinetics Pharmaceuticals, Inc. 6Z4.F Financial and Trading Overview
| Crinetics Pharmaceuticals, Inc. stock price | 44.8 EUR |
| Previous Close | 19 EUR |
| Open | 18.8 EUR |
| Bid | 18.8 EUR x 0 |
| Ask | 19.2 EUR x 0 |
| Day's Range | 18.8 - 18.8 EUR |
| 52 Week Range | 14 - 21.6 EUR |
| Volume | 280 EUR |
| Avg. Volume | 5 EUR |
| Market Cap | 1.02B EUR |
| Beta (5Y Monthly) | 0.94084 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.44 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38 EUR |
6Z4.F Valuation Measures
| Enterprise Value | 787.22M EUR |
| Trailing P/E | N/A |
| Forward P/E | -6.2666664 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 238.19357 |
| Price/Book (mrq) | 3.6209552 |
| Enterprise Value/Revenue | 183.716 |
| Enterprise Value/EBITDA | -4.349 |
Trading Information
Crinetics Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 0.94084 |
| 52-Week Change | 23.74% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 21.6 EUR |
| 52 Week Low | 14 EUR |
| 50-Day Moving Average | 17.93 EUR |
| 200-Day Moving Average | 17.7 EUR |
6Z4.F Share Statistics
| Avg. Volume (3 month) | 5 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 54.03M |
| Float | 42.45M |
| Short Ratio | N/A |
| % Held by Insiders | 2.90% |
| % Held by Institutions | 106.22% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4248.14% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -35.15% |
| Return on Equity (ttm) | -60.094% |
Income Statement
| Revenue (ttm) | 4.29M EUR |
| Revenue Per Share (ttm) | 0.08 EUR |
| Quarterly Revenue Growth (yoy) | -14.39% |
| Gross Profit (ttm) | -125488000 EUR |
| EBITDA | -181007008 EUR |
| Net Income Avi to Common (ttm) | -175286000 EUR |
| Diluted EPS (ttm) | -3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 296.12M EUR |
| Total Cash Per Share (mrq) | 5.48 EUR |
| Total Debt (mrq) | 2.82M EUR |
| Total Debt/Equity (mrq) | 1.01 EUR |
| Current Ratio (mrq) | 11.603 |
| Book Value Per Share (mrq) | 5.192 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -142380000 EUR |
| Levered Free Cash Flow (ttm) | -78527624 EUR |
Profile of Crinetics Pharmaceuticals, Inc.
| Country | Germany |
| State | CA |
| City | San Diego |
| Address | Building No. 2 |
| ZIP | 92121 |
| Phone | 858 450 6464 |
| Website | https://www.crinetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 210 |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.
Q&A For Crinetics Pharmaceuticals, Inc. Stock
What is a current 6Z4.F stock price?
Crinetics Pharmaceuticals, Inc. 6Z4.F stock price today per share is 44.8 EUR.
How to purchase Crinetics Pharmaceuticals, Inc. stock?
You can buy 6Z4.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Crinetics Pharmaceuticals, Inc.?
The stock symbol or ticker of Crinetics Pharmaceuticals, Inc. is 6Z4.F.
Which industry does the Crinetics Pharmaceuticals, Inc. company belong to?
The Crinetics Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Crinetics Pharmaceuticals, Inc. have in circulation?
The max supply of Crinetics Pharmaceuticals, Inc. shares is 77.93M.
What is Crinetics Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Crinetics Pharmaceuticals, Inc. PE Ratio is now.
What was Crinetics Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Crinetics Pharmaceuticals, Inc. EPS is -3.44 EUR over the trailing 12 months.
Which sector does the Crinetics Pharmaceuticals, Inc. company belong to?
The Crinetics Pharmaceuticals, Inc. sector is Healthcare.